Optimi Health CorpOTCQX International:OPTHFView on Canadian Exchange
- LAST PRICE0.1860
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.1860/ 50
- Ask / Lots0.2452/ 25
- Open / Previous Close0.0000 / 0.1860
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | OPTHF |
|---|---|---|
| 10:48 ET | 500 | 0.186 |
| 11:09 ET | 1000 | 0.2048 |
| 11:38 ET | 110 | 0.186 |
Apr 15, 2024
Optimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API), from 8:01AM ET on Monday Apr 15, 2024 by Dow Jones
8:01AM ET on Monday Apr 15, 2024 by Dow Jones
Apr 9, 2024
Optimi Health Signs Psilocybin Supply Agreement With New Zealand-Based M tai Medical Research Institute, from 9:13AM ET on Tuesday Apr 09, 2024 by Dow Jones
9:13AM ET on Tuesday Apr 09, 2024 by Dow Jones
Apr 2, 2024
Optimi Health Receives Finished Product Test Results and Certificate Of Analysis for GMP Natural Psilocybin Extract, from 7:30AM ET on Tuesday Apr 02, 2024 by Dow Jones
7:30AM ET on Tuesday Apr 02, 2024 by Dow Jones
Mar 28, 2024
Optimi Health Confirms Presenting Sponsorship at the 4th Annual Psychedelic Therapeutics and Drug Development Conference, from 7:30AM ET on Thursday Mar 28, 2024 by Dow Jones
7:30AM ET on Thursday Mar 28, 2024 by Dow Jones
Mar 26, 2024
Optimi Health to Supply MDMA for Psychedelic Research at Tel Aviv University, from 7:30AM ET on Tuesday Mar 26, 2024 by Dow Jones
7:30AM ET on Tuesday Mar 26, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Optimi Health Corp | 23.2M | 0.0x | --- |
Company Information
Optimi Health Corp. is an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes, psychedelic substances, such as 3,4-Methylenedioxymethamphetamine (MDMA), natural Manufacturing Practices (GMP)-grade psilocybin, as well as functional mushrooms that focus on the health and wellness markets. The Company produces scalable psychedelic formulations for transformational human experiences. Its products are grown and manufactured at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia. It is a supplier of drug and nutraceutical products. The Company works with customers, health food distributors, and drug developers, and patients regulated by Health Canada.
Contact Information
- Headquarters
- 21 Water St #600VANCOUVER, BC, Canada V6B 1A1
- Phone
- 778-761-4551
- Fax
- ---
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $23.2M |
|---|---|
Revenue (TTM) | $238.6K |
Shares Outstanding | 89.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.06 |
Book Value | $0.15 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 97.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,233.99% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
